How should we best target the biology of ER PR HER2 negative breast cancer?

The molecular pathology of ER, PR HER2 n

The molecular pathology of ER, PR HER2 negative breast cancers: finding novel biomarkers

✍ J.S. Reis-Filho; A. Tutt 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Descriptive analysis of estrogen recepto

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype : A population-based study from the California cancer Registry

✍ Katrina R. Bauer; Monica Brown; Rosemary D. Cress; Carol A. Parise; Vincent Cagg 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

## Abstract ## BACKGROUND. Tumor markers are becoming increasingly important in breast cancer research because of their impact on prognosis, treatment, and survival, and because of their relation to breast cancer subtypes. The triple‐negative phenotype is important because of its relation to the b